The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
An article from
Dive Brief
The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
Published Aug. 31, 2026
Illustration of an antibody (immunoglobulin) molecule, showing its Y-shaped structure. On Aug. 31, 2026, Eli Lilly announced it is buying Merida Biosciences in a deal to develop drugs targeting autoantibodies that cause autoimmune disorders.
Eli Lilly buying Merida Biosciences for up to $2.875 billion
Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
Eli Lilly compra empresa de biotecnologia Merida Biosciences por até US$ 2,87 bi
Dona do Mounjaro compra empresa que testa tratamentos contra doenças autoimunes por US$ 2,88 bi
Pharmaindustrie: Eli Lilly stärkt Immunologiegeschäft mit Milliardenzukauf
The deal adds a pipeline targeting the antibodies behind Graves' disease, thyroid eye disease, food allergy, and other conditions
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 for…
Empresa informou que a Merida está desenvolvendo uma nova classe de terapias de precisão para graves doenças autoimunes e…
Eli Lilly adquire Merida, que desenvolve tratamento contra doença de Graves
Bis zu 2,88 Milliarden Dollar gibt der Pharmakonzern für die Übernahme der Biotechfirma Merida Biosciences aus. Finanziert wird…
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an…
